Evidence map›Paper›PMID 40072605›Full record

ArticleWorld journal of urology2025

Correction: Can we rely on magnetic resonance imaging for prostate cancer detection and surgical planning? Comprehensive analysis of a large cohort of patients undergoing transperineal mapped biopsies.

Nidia Gómez Diez, Pedro de Pablos-Rodríguez, David Sánchez-Mateos Manzaneque, María Isabel Martín García, Paula Pelechano Gómez, María Barrios Benito, Ana Calatrava Fons, Jessica Aliaga Patiño, Juan Boronat Catalá, Álvaro Gómez-Ferrer Lozano and 7 more

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Focal Cryotherapy in Prostate Cancer. Does Gleason Impact Results?International braz j urol : official journal of the Brazilian Society of Urology
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Nidia Gómez DiezUrology Department. Urosalud. La Salud Hospital, Valencia, 46021, Spain.ORCID http://orcid.org/0000-0002-7533-4190
Pedro de Pablos-RodríguezUrology Department, Valencian Institute of Oncology Foundation (FIVO), Valencia, 46009, Spain. pdepablos@fivo.org.ORCID http://orcid.org/0000-0003-2286-9893
David Sánchez-Mateos ManzanequeUrology Department, Toledo General Hospital, Toledo, 45007, Spain.
María Isabel Martín GarcíaRadiology Department, Valencian Institute of Oncology Foundation (FIVO), Valencia, 46009, Spain.
Paula Pelechano GómezRadiology Department, Valencian Institute of Oncology Foundation (FIVO), Valencia, 46009, Spain.
María Barrios BenitoRadiology Department, Valencian Institute of Oncology Foundation (FIVO), Valencia, 46009, Spain.
Ana Calatrava FonsPathology Department, Valencian Institute of Oncology Foundation (FIVO), Valencia, 46009, Spain.
Jessica Aliaga PatiñoPathology Department, Valencian Institute of Oncology Foundation (FIVO), Valencia, 46009, Spain.
Juan Boronat CataláUrology Department, Valencian Institute of Oncology Foundation (FIVO), Valencia, 46009, Spain.
Álvaro Gómez-Ferrer LozanoUrology Department, Valencian Institute of Oncology Foundation (FIVO), Valencia, 46009, Spain.
Augusto Wong GutiérrezUrology Department, Valencian Institute of Oncology Foundation (FIVO), Valencia, 46009, Spain.
Ángel García CortésUrology Department, Valencian Institute of Oncology Foundation (FIVO), Valencia, 46009, Spain.
Miguel Ramírez BackhausUrology Department, Valencian Institute of Oncology Foundation (FIVO), Valencia, 46009, Spain.
Juan Casanova Ramón BorjaUrology Department, Valencian Institute of Oncology Foundation (FIVO), Valencia, 46009, Spain.
Manel Beamud CortésUrology Department, Valencian Institute of Oncology Foundation (FIVO), Valencia, 46009, Spain.
José Luis Domínguez EscrigUrology Department, Valencian Institute of Oncology Foundation (FIVO), Valencia, 46009, Spain.
Antonio Coy GarcíaStatistic Department, Valencia Instituto of Oncology Foundation (FIVO), Valencia, 46009, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate MRI and histological concordance in prostate cancer (PCa) identification via mapped transperineal biopsies. METHODOLOGY: Retrospective per-lesion analysis of patients undergoing MRI and transperineal biopsy at the Valencian Institute of Oncology (2016-2024) using CAPROSIVO PCa data. Patients underwent MRI, with or without regions of interest (ROI), followed by transperineal biopsies (3-5 cores/ROI, 20-30 systematic). Sensitivity (Se), specificity (Sp), negative predictive value (NPV), positive predictive value (PPV), and area under the curve (AUC) were calculated, considering PI-RADS 3 lesions as positive or negative. Gleason Grade Group (GG) > 1 defined clinically significant PCa (csPCa).

results1817 lesions were analyzed from 1325 patients (median age 67, median PSA 6.3 ng/ml). 53% MRI were negative, GG > 1 prevalence was 29.1%. MRI-negative cases showed varying PCa rates: 57.4% negative, 34.3% GG 1, and 8.3% GG > 1. PI-RADS 3 lesions had mixed outcomes: 45.6% benign, 29.5% GG 1, and 24.9% GG > 1. 9.2% PI-RADS 4-5 lesions were negative, 23% GG 1, and 67.8% GG > 1. For PI-RADS 3 lesions considered positive, Se, Sp, NPV, PPV, and AUC were 84.9%, 68.4%, 91.7%, 52.6%, and 0.77 respectively. Considering PI-RADS 3 as negative yielded 70.6% Se, 86.2%, Sp, 87.7% NPV, 67.8% PPV, and 0.78 AUC.

conclusionMRI and mapped prostate biopsies exhibited moderate concordance. MRI could miss up to one in ten csPCa foci and misinterpret one in two ROIs. Careful MRI interpretation is crucial for optimizing patient care.

Indexed as

MRIPI-RADS 3Prostate cancerTransperineal biopsy

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.